Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $2,195,000 | $1,313,000 | $2,462,000 | $76,000 |
| Dep. & Amort. | $1,011,000 | $1,011,000 | $1,012,000 | $1,880,000 |
| Deferred Tax | -$359,000 | -$437,000 | $223,000 | -$791,000 |
| Stock-Based Comp. | $139,000 | $137,000 | $144,000 | $120,000 |
| Change in WC | $3,055,000 | $15,000 | -$1,871,000 | $1,276,000 |
| Other Non-Cash | $270,000 | $1,878,000 | -$16,000 | $1,878,000 |
| Operating Cash Flow | $6,311,000 | $3,917,000 | $1,954,000 | $4,439,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$320,000 | -$361,000 | -$260,000 | -$378,000 |
| Net Acquisitions | -$2,387,000 | -$15,000 | $165,000 | $286,000 |
| Inv. Purchases | -$665,000 | -$621,000 | -$636,000 | -$371,000 |
| Inv. Sales/Matur. | $878,000 | $524,000 | $232,000 | $267,000 |
| Other Inv. Act. | $792,000 | $0 | $0 | $0 |
| Investing Cash Flow | -$1,702,000 | -$473,000 | -$499,000 | -$196,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$224,000 | -$585,000 | $368,000 | -$405,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$1,263,000 | -$1,262,000 | -$1,258,000 | -$1,218,000 |
| Other Fin. Act. | -$3,000 | $11,000 | -$103,000 | -$19,000 |
| Financing Cash Flow | -$1,490,000 | -$1,836,000 | -$993,000 | -$1,642,000 |
| Forex Effect | -$4,000 | $128,000 | $66,000 | -$147,000 |
| Net Chg. in Cash | $3,115,000 | $1,736,000 | $528,000 | $2,454,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $12,611,000 | $10,875,000 | $10,347,000 | $7,893,000 |
| End Cash | $15,726,000 | $12,611,000 | $10,875,000 | $10,347,000 |
| Free Cash Flow | $5,991,000 | $3,556,000 | $1,694,000 | $4,061,000 |